Easywell Biomedicals, Inc. (TPEX: 1799)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
66.60
-1.30 (-1.91%)
Dec 2, 2024, 1:30 PM CST

Easywell Biomedicals Company Description

Easywell Biomedicals, Inc. develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia.

It develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; and TLX-011 for treatment of inflammatory lesions of rosacea.

The company also develops TWB-201 for Parkinson patch; TLX-501, an urinary medicine; and TLX-502, a pneumonia medicine, as well as provides medical devices.

It has a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience, LLC for the development of TLX-050 for the treatment of neurological disorders.

The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015.

Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.

Easywell Biomedicals, Inc.
Country Taiwan
Founded 1998
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
CEO James Aiping Lee

Contact Details

Address:
No.10, Yanfa 2nd Road
Hsinchu City, 30076
Taiwan
Phone 886 3 666 9596
Website easywellbio.com

Stock Details

Ticker Symbol 1799
Exchange Taipei Exchange
Fiscal Year January - December
Reporting Currency TWD
ISIN Number TW0001799005
SIC Code 3829

Key Executives

Name Position
James Aiping Lee Ph.D. Manager and President
Dr. Yu-Hsing Tu Ph.D. Chief Science Officer
Dr. She Bin-Ru Ph.D. Chief Technical Officer of Regenerative Medicine Division